Mireille Kamariza, CEO of OliLux Biosciences — which recently received an investment from Open Philanthropy — is working on a potential breakthrough diagnostic tool to fight tuberculosis.
Kainomyx, which Open Philanthropy has invested in, is attacking a set of diseases that devastates developing countries but also carry risks to other nations with increased worldwide travel.
This federal grant will help support Phase I and II clinical trials over the next 5 years with a goal of providing a new effective once-daily, oral, and...
